Getting Past China’s Coronavirus

KNOWING WHERE TO FIND THE RICHEST TREASURES IN OUR RACES FOR THE CURES

The path were journeying together, comes from; The Who’s Who of noted individual’s within their field of expertise. They are associated with Real-Life Collaborations within Higher Learning Institutions University, and within Battle-Tested Biopharmaceutical Company’s—heavily shrouded with many Proofs of Concept in U.S. Patents. These Worldwide Patents are Winning the Wars in Life over Death outcomes, as this is where the TREASURE Will Always BE FOUND.IN "ROI" RETURN ON INVESTMENT. 

GeneOne Life Science Copyright January 2020

The most recent Pandemic out of China sends a message of why CEPI’s $9 Million Dollar—Get This Figured Out Now, Chose Inovio Pharmaceuticals INO. The corporation is heavily weighted with many U.S. Patents and Worldwide License Agreements, with collaborations being real head turners. The Point & Figure Chart from back in December revealed an interesting Catapult signal bringing us our buy-in $2.25 of over 90,000 shares. Please review below: 

(Click on image to enlarge)

Why this matters as caught above, are SIMPLE. The institutions have entered the playing field of "X's" instead of "O's". So when did China actually report the major warnings of their Coronavirus and the World's mainstream media run the news? This becomes the real narrative of this article today.

The "Real Quant Research Tanks" know where all the real Patents are lying within the intellectual treasure chests. This is also true for CEPI awarding Inovio the many millions of dollars. These dollars towards bringing novel drug vaccines and cures to our worldwide stage of biological threats living among us as the Coronavirus has. In fact, recently presented by Inovio CEO Dr. Kim stated worldwide right now, “there are over 80 million people infected with the HPV viruses.” It’s a staggering number, to say the least! With viruses and the battle against many forms of Cancers, Inovio Pharmaceuticals is getting very close to achieving Orphan FDA approval on a few of INO Pipeline projects. 

REMEMBERING OUR OTHER RECENT BUY CALL ON DERMIRA., INC., DERM 

(Click on image to enlarge)

The price targets have come to be hit by DERM. We are predicting the price targets for Inovio Pharmaceuticals 

TipRanks All Rights Reserved (c) January 2020

The timing and adjusting Buy orders for INO is entering quickly upon those wanting the highest ROI.

 Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.  

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with
James Gornick 4 years ago Contributor's comment

Was recently over the last hour, what do we see as INO real Price-TARGET’s over these next 6-14 Months?

We actually see the stock picking up new Analyst Upgrades with Updated Analysts Notes.

Most likely for Inovio INO may see their Share Prices jump as Regeneron had travelled when clearing the hurdles of locking in Proof of Concept.

We see their Price topping well over the $68 - $79 dollar a share just based on the HPV epidemic on met to this current discussion thread.

This doesn’t even include their other Pipeline Projects making great strides towards early Orphan Drug FDA approval.

Hopefully this answers those sending out to me their current questions addressing Inovio Pharmaceuticals in the near-term horizon of potential ROI

Ayelet Wolf 4 years ago Member's comment

Fascinating, thanks.